We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Life Science Pharmaceuticals Acquires Monoclonal Antibody Programs from LICR

Life Science Pharmaceuticals Acquires Monoclonal Antibody Programs from LICR

Life Science Pharmaceuticals Acquires Monoclonal Antibody Programs from LICR

Life Science Pharmaceuticals Acquires Monoclonal Antibody Programs from LICR

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Life Science Pharmaceuticals Acquires Monoclonal Antibody Programs from LICR"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Life Science Pharmaceuticals has announced that it has completed an exclusive world-wide license to commercially develop three monoclonal antibodies which represent potential therapies for cancer and autoimmune diseases.

Under the leadership of Dr. Lloyd J. Old, Senior Scientific Advisor to the Company, LICR has performed the most comprehensive cancer cell surface mapping and targeting studies in the field.

These studies have yielded a portfolio of well characterized and target-specific monoclonal antibodies.

The selectivity of each product candidate has been validated in humans by demonstrating safety and targeting in clinical studies.

The Company plans to exploit the targeting attributes of certain product candidates by attaching tumor-fighting payloads to the antibodies.

The Company's lead product candidate, antibody 806 targets a unique epitope in the Epidermal Growth Factor Receptor (EGFR). This distinct target is present on cancer cells but not available on normal cells.

Currently approved EGF targeting drugs Erbitux® and Tarceva® target the wild-type receptor which is also present in normal skin and liver cells.

The Company believes the unique targeting attributes of 806 may represent a paradigm of cancer treatment via the EGFR pathway.

The second antibody in the Company's pipeline, targets FAP (fibroblast activating protein) present on the surface of tumor stroma cells.

The company believes anti-FAP-alpha antibodies represent a significant market opportunity because they target the tumor micro-environment rather than the tumor itself.

Thus, this antibody may benefit patients suffering with multiple types of solid tumors.

A33, the third antibody acquired by the company targets colorectal cancer and is currently the focus of clinical trials at the Memorial Sloan Kettering Cancer Center and The LICR Melbourne Center for Clinical Studies.

"In one transaction, Life Science Pharmaceuticals has acquired a diverse portfolio of exciting clinical stage product candidates," noted James Fiore, President and CEO of the Company.

"We have also structured close collaborations with key scientific personnel at the Ludwig Institute, providing a smooth transition from academic to commercial development," Mr. Fiore added.